FOTIVDA is Aveo’s marketed product for treating advanced renal cell carcinoma, primarily used as a later line agent in the management of metastatic disease. The ongoing TiNivo-2 study aims to compare the efficacy of FOTIVDA alone, administered at its approved dose, with FOTIVDA in combination with nivolumab, a checkpoint inhibitor developed by Bristol-Myers Squibb. The study is expected to complete accrual soon, with results anticipated within the next year or year and a half.
With LG’s support, Aveo has embarked on exploring the potential of FOTIVDA in other indications through sponsored studies and investigator-initiated trials. They are particularly interested in investigating novel combinations of FOTIVDA with emerging agents, not limited to renal cell cancer but extending to various other diseases.
Umab, an antibody targeting hepatocyte growth factor (HGF), has shown encouraging phase two data in combination with Cetuximab for advanced head and neck cancer. Aveo plans to initiate a phase three registrational program for Umab before the end of this year.
AV-380, an early-stage molecule, is an antibody targeting GDF-15 that holds promise for the treatment of cancer cachexia. Cachexia is a debilitating comorbid condition observed in patients with advanced malignancies, which can hinder the delivery of effective treatment. By addressing or preventing cachexia, Aveo aims to improve treatment outcomes for these patients when receiving standard care.
The LG acquisition has revitalized Aveo’s interest in business development, leading them to actively seek new molecules through licensing or acquisition. They are open to various deal structures and are actively engaging with potential partners at Bio in Boston and other events.
Aveo Oncology is committed to a patient-centric approach, resonating with the ASCO theme. The company’s motto of passionately pursuing a better life for cancer patients holds true, and this patient-focused commitment is acknowledged by key opinion leaders, investigators, and patient advocacy groups. Working at Aveo is a rewarding experience, as the company’s DNA revolves around keeping the patient at the center of all endeavors.